spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PCI Pharma Services Announces Serialization Installation at Tredegar Manufacturing Center of Excellence

PCI’s Tredegar site is the latest site to offer full Serialization services to global customers

PCI Pharma Services (PCI) is pleased to announce the installation and validation of its latest comprehensive Serialization system, located at its manufacturing Center of Excellence in Tredegar, UK.  The investment demonstrates PCI’s continued investment in and expansion of market-leading Serialization capabilities. This latest installation increases PCI’s Serialization capability to support clients in advance of implementation dates for the European Falsified Medicines Directive (EU FMD), as well as supply for the US and emerging markets, including countries such as China, Turkey, Brazil, Saudi Arabia and others.  PCI’s system is compliant to all EU member country requirements for Serialization and specialized labeling, including application and integration of advanced Anticounterfeiting technologies.

 

The highly flexible technology delivers machine and human-readable coding, tamper evident solutions and Bollini labeling – which in turn is linked to a case loading and aggregation station, with a final aggregation station connecting cases to pallet. PCI is a strong supporter of the advanced use of aggregation to support product security, realizing the significant benefits in packaging operations, as well as the broader pharmaceutical supply chain.

 

PCI’s site in Tredegar, South Wales, UK already offers excellence in potent manufacturing services for customers globally, and this new Serialization technology further strengthens its comprehensive offering. This investment in the Tredegar facility is part of a significant global initiative to develop the Serialization services across PCI’s global network, which will ultimately exceed more than 90 lines.

 

Commenting on this latest investment, Jim Neville, Director of Operations, Tredegar, stated: “This is an important addition to the site’s capabilities. Being able to offer this fully flexible service and work in partnership with our customers to deliver a trusted, seamless service is critical, and being ahead of the timelines with this offering ensures compliance with the EU FMD.

 

PCI has been actively Serializing commercial products for the US, European and international markets for the past six years, and this investment in the Tredegar capabilities continues to demonstrate PCI’s market-leading position. The integrated technology strategy enables operators in all PCI’s global locations to operate the same graphical user interface, providing a seamless global service.  PCI clients enjoy singular connectivity to all PCI sites through a best-in-class platform.  PCI is dedicated to maintaining a leadership position at the forefront of the Serialization initiative and providing clients with an industry-leading customer experience.

 

To find out more about PCI, please visit www.pciservices.com

 

About PCI Pharma Services  

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives.  For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.

 

 

Contact

 

Tom Gosschalk / Carrie Lowe at becg

tom.gosschalk@becg.com / carrie.lowe@becg.com             

 

T: +44 (0)203 697 7647 / +44 (0)1962 893 913

 
Print this page
Send to a friend
   
spacer
News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>


White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

Industry Events

SMi’s 9th Annual Biosimilars & Biobetters Conference

25-27 September 2018, Copthorne Tara Hotel, London, UK

Following the success of our previous events in both London and the US, Biosimilars and Biobetters UK 2018, SMi deliver a stellar speaker line-up and bring together a global audience of biosimilar experts to discuss the latest developments and future of the rapidly evolving and expanding biosimilars market.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement